Euroopa Liit - eesti - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastilised ained - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Euroopa Liit - eesti - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - antineoplastilised ained - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekursorko-lümfoblastne leukeemia-lümfoom - antineoplastilised ained - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Euroopa Liit - eesti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumab - mitu müeloomit - antineoplastilised ained - empliciti on näidustatud kombinatsioonis lenalidomide ja deksametasooni raviks hulgimüeloom täiskasvanud patsientidel, kes on saanud vähemalt ühe eelneva ravi (vt lõigud 4. 2 ja 5.

Eesti - eesti - Ravimiamet

apeiron biologics ag - beetadinutuksimab - infusioonilahuse kontsentraat - 4,5mg 1ml 4.5ml 10tk; 4,5mg 1ml 4.5ml 1tk

Eesti - eesti - Ravimiamet

f. hoffmann-la roche ltd - polatuzumabvedotiin - infusioonilahuse pulber - 140mg 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - lümfoom, b-raku - antineoplastilised ained - polivy koos bendamustine ja rituksimabi on näidustatud ravi täiskasvanud patsientidel, kellel on taastekkinud/tulekindlad hajus suur b-rakulise lümfoomi (dlbcl), kes ei ole kandidaadid vereloome tüvirakkude siirdamist. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Eesti - eesti - Ravimiamet

janssen cilag international nv - amivantamab - infusioonilahus - 50mg 1ml 7ml 1tk

Eesti - eesti - Ravimiamet

genentech inc. - glofitamab - infusioonilahuse kontsentraat - 5mg 1ml 2ml 1tk

Eesti - eesti - Ravimiamet

patheon manufacturing services llc - teklistamab - süstelahus - 90mg 1ml 1.7ml 1tk